The IL-13 monoclonal antibodies (e.g., dupilumab, lebrikizumab, and tralokinumab) have been developed for not only allergic diseases (e.g., atopic dermatitis, asthma) (37) but various other autoimmune diseases (38). The gene discussed is IL13; the disease is atopic eczema.